- Home
- BBIO
as 02-21-2025 4:00pm EST
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | PALO ALTO |
| Market Cap: | 5.6B | IPO Year: | 2019 |
| Target Price: | $52.27 | AVG Volume (30 days): | 2.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.88 | EPS Growth: | N/A |
| 52 Week Low/High: | $21.62 - $39.47 | Next Earning Date: | 02-20-2025 |
| Revenue: | $221,902,000 | Revenue Growth: | 2285.27% |
| Revenue Growth (this year): | 2306.75% | Revenue Growth (next year): | -15.98% |
Stock Insider Trading Activity of BridgeBio Pharma Inc. (BBIO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| VIKING GLOBAL INVESTORS LP | BBIO | 10% Owner | Jan 31 '25 | Sell | $34.90 | 3,065,616 | $106,989,998.40 | 22,055,375 | |
| Kumar Neil | BBIO | Chief Executive Officer | Jan 28 '25 | Sell | $36.48 | 600,000 | $21,788,650.42 | 5,371,515 | |
| STEPHENSON BRIAN C | BBIO | Secretary, Treasurer & CFO | Jan 28 '25 | Sell | $36.29 | 68,000 | $2,467,760.80 | 93,758 |
Latest BridgeBio Pharma Inc. News
BBIO Breaking Stock News: Dive into BBIO Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
Cantor Fitzgerald Adjusts BridgeBio Pharma Price Target to $95 From $70, Maintains Overweight Rating
GuruFocus.com
2 days ago
BridgeBio Pharma Inc (BBIO) Q4 2024: Everything You Need To Know Ahead Of Earnings
Zacks
2 days ago
BridgeBio Pharma (BBIO) Reports Q4 Loss, Tops Revenue Estimates
MT Newswires
2 days ago
BridgeBio Pharma Q4 Loss Widens, Revenue Rises -- Shares Up Pre-Bell
Associated Press Finance
2 days ago
BridgeBio Pharma: Q4 Earnings Snapshot
GlobeNewswire
2 days ago
BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update
BioPharma Dive
2 days ago
BridgeBio’s heart drug launch gets off to a fast start
MT Newswires
2 days ago
BridgeBio Pharma Insider Sold Shares Worth $1,140,024, According to a Recent SEC Filing
Compare BBIO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BBIO BridgeBio Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.